News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,838 Results
Type
Article (39692)
Company Profile (247)
Press Release (658899)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204166)
Career Advice (2007)
Deals (35418)
Drug Delivery (95)
Drug Development (81044)
Employer Resources (172)
FDA (16180)
Job Trends (14859)
News (345185)
Policy (32538)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49432)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2257)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (151)
Cell therapy (423)
Cervical cancer (19)
Clinical research (65986)
Collaboration (832)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2205)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86635)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112409)
Executive appointments (722)
FDA (17442)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (748)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (709)
Government (4416)
Grass and pollen (4)
Guidances (67)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16508)
IRA (40)
Job creations (3631)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13377)
Medtech (13382)
Mergers & acquisitions (19455)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57299)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20557)
Phase II (29056)
Phase III (21649)
Pipeline (1203)
Policy (139)
Postmarket research (2563)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22282)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (689)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (156)
Last 7 days (930)
Last 30 days (2623)
Last 365 days (32770)
2025 (10732)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46540)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37839)
Australia (6184)
California (6134)
Canada (2016)
China (523)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81249)
Florida (912)
Georgia (206)
Idaho (57)
Illinois (536)
India (25)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4568)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1726)
New Mexico (28)
New York (1746)
North Carolina (967)
North Dakota (8)
Northern California (2682)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1377)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2303)
Tennessee (101)
Texas (906)
United States (23124)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (551)
West Virginia (3)
Wisconsin (54)
698,838 Results for "diasorin inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc.(Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.
February 13, 2023
·
9 min read
Deals
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.
February 28, 2023
·
6 min read
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
Press Releases
RxSight, Inc. to Present at the Bank of America Healthcare Conference
May 1, 2025
·
1 min read
Policy
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.
November 29, 2021
·
7 min read
Press Releases
Innovative Lab Services LLC Acquires Compco Analytical, Inc.
May 1, 2025
·
1 min read
Press Releases
Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
April 30, 2025
·
3 min read
Press Releases
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference
April 29, 2025
·
1 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
Press Releases
Penumbra, Inc. Reports First Quarter 2025 Financial Results
April 23, 2025
·
15 min read
1 of 69,884
Next
